SANDRIL Drug Patent Profile

When do Sandril patents expire, and what generic alternatives are available?

Sandril is a drug marketed by Lilly and is included in two NDAs.

The generic ingredient in SANDRIL is reserpine. There are nineteen drug master file entries for this compound. Additional details are available on the reserpine profile page.

Summary for SANDRIL

US Patents:	0
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	1,705
DailyMed Link:	SANDRIL at DailyMed

US Patents and Regulatory Information for SANDRIL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lilly	SANDRIL	reserpine	INJECTABLE;INJECTION	010012-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Lilly	SANDRIL	reserpine	TABLET;ORAL	009376-004	Approved Prior to Jan 1, 1982		DISCN	No	No
Lilly	SANDRIL	reserpine	TABLET;ORAL	009376-001	Approved Prior to Jan 1, 1982		DISCN	No	No

SANDRIL Market Dynamics and Financial Trajectory

Last updated: April 26, 2026

SANDRIL’s market dynamics and financial trajectory cannot be produced accurately from the information provided. A complete, citation-backed analysis requires verified details on the product identity (active ingredient, dosage form, strength), geography (country-level commercialization), and the specific corporate/market financial disclosures tied to “SANDRIL” (revenue, net sales, launch timing, and payer context). Without those, any market sizing, demand mapping, pricing path, channel mix, or earnings trajectory would risk being wrong.

What is SANDRIL and where is it sold?

No validated product definition or commercialization footprint is provided for “SANDRIL.”

What are the market drivers and demand constraints?

No validated information is provided on:

• Indication scope and clinical positioning
• Competitor set and therapeutic alternatives
• Pricing and reimbursement status
• Formulation constraints (e.g., manufacturing capacity, supply continuity)
• Regulatory status (approvals, label changes, and exclusivity)

How does SANDRIL’s financial trajectory look (sales, profitability, and outlook)?

No validated financial data is provided for:

• Net sales or revenue by year
• Gross margin / COGS drivers
• Selling and marketing expense intensity
• Distribution model and trade terms
• Litigation, generic entry, or patent expiry events

What does the competitive landscape imply for SANDRIL’s pricing power?

No validated data is provided on:

• Generic and biosimilar entry risk (if applicable)
• Therapeutic class pricing trends
• Payer preferred product lists and tender dynamics
• Expected switching behavior

What timelines matter for commercialization and value realization?

No validated dates are provided for:

• First launch date and subsequent label expansions
• Patent expiry, exclusivity end, and regulatory milestones
• Any safety signals, label restrictions, or REMS-type constraints
• Supply interruptions or manufacturing scale-ups

Key Takeaways

• A complete market and financial trajectory for SANDRIL cannot be generated from the current inputs without risking factual error.
• Deliverable requirements for a Bloomberg-style trajectory analysis include verified product identity, geographies, and financial disclosure linkage, plus citation-backed commercialization and patent/regulatory timelines.
• No market, competitive, or financial trajectory assertions are made here because no validated source data is available in the prompt.

FAQs

1. What does “SANDRIL” refer to (active ingredient and dosage form)?
   Not specified in the provided information.

2. Which countries and channels sell SANDRIL?
   Not specified in the provided information.

3. What is the current sales scale and growth rate for SANDRIL?
   Not provided in the prompt.

4. When do key patent or exclusivity milestones occur for SANDRIL?
   Not provided in the prompt.

5. Who competes with SANDRIL in its indication(s), and how does pricing evolve?
   Not provided in the prompt.

References

[1] No sources were provided or identifiable from the prompt to cite.